About

We conduct clinical trials and observational studies in the areas of brain and spine disorders. This includes memory loss, dementia, stroke, Parkinson’s disease and spinal cord injury. Our neuroscience research teams work through  Struthers Parkinson's Center and the Center for Memory & Aging.  An additional area of focus is on intranasal drug delivery.
Affiliation
people
Faculty Position
  • Barclay, Terry R., PhD, LP, Research investigator, Center for Memory & Aging, Regions Hospital 2009 -
  • Fine, Jared M., PhD, Research Associate 2006 -
  • Frey II, William H., PhD, Sr. Director 1977 -
  • Guliani, Gaurav K., MD, Research Investigator
  • Hanson, Leah R., PhD, Sr. Director
  • Herrmann, Amanda A., PhD, Research Associate 2021 -
  • Jackson, Steven D., MD, Research Investigator
  • Johnson, Julia C, MD, Research Investigator
  • Kashyap, Bhavani, MBBS, PhD, Research Associate 2017 -
  • Nance, Martha A., MD, Research Investigator
  • Parashos, Sotirios A., MD, PhD, Research Investigator
  • Rosenbloom, Michael H., MD, Director 2010 -
  • Wyman-Chick, Kate A., PsyD, ABPP, Investigator and Clinical Neuropsychologist at HealthPartners Neuroscience Center
    • Publications While At Healthpartners
    selected publications
    Journal Article
  • A case of minimally progressive prodromal Alzheimer's disease. 
    Journal of Alzheimer's disease reports. 2023
  • Potentially Preventable Readmissions after Acute Inpatient Rehabilitation. 
    American Journal of Physical Medicine and Rehabilitation. 2023
  • A non-invasive direct nose to brain drug delivery platform vs. invasive brain delivery approach: patient-centered care impact analysis. 
    Drug delivery. 2022
  • Assessment of deep brain stimulation candidacy during the COVID-19 pandemic: lessons learned and future directions for neuropsychologists. 
    Clinical Neuropsychologist. 2022
  • Brief visuospatial memory test-revised normative data and form equivalency for adults ages 80-89. 
    Clinical Neuropsychologist. 2022
  • Hip fracture care in Parkinson disease: a retrospective analysis of 1,239 patients. 
    Geriatric orthopaedic surgery & rehabilitation. 2022
  • Intranasal insulin attenuates the long-term adverse effects of neonatal hyperglycemia on the hippocampus in rats. 
    Developmental Neuroscience. 2022
  • Patterns and predictors of extra-corporeal membrane oxygenation related cerebral microbleeds. 
    Journal of Stroke and Cerebrovascular Diseases. 2022
  • Prodromal dementia with Lewy bodies: evolution of symptoms and predictors of dementia onset. 
    Journal of Geriatric Psychiatry and Neurology. 2022
  • Rate and predictors of acute care encounters in the first month after stroke. 
    Journal of Stroke and Cerebrovascular Diseases. 2022
  • Readmission to an acute care hospital during inpatient rehabilitation after stroke. 
    American Journal of Physical Medicine and Rehabilitation. 2022
  • Responding to the needs of persons living with dementia and their caregivers during the COVID-19 pandemic: lessons from the Care Ecosystem. 
    Innovation in aging. 2022
  • Tools for communicating risk for Parkinson's disease. 
    NPJ Parkinson's disease. 2022
  • A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease. 
    Drugs and Aging. 2021
  • A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson’s disease who are treated with Levodopa-Carbidopa Intestinal Gel and deep brain stimulation: the PD-DUAL Study. 
    Neurology. 2021
  • Barriers to achieving target door-to-needle time in patients treated with IV thrombolysis. 
    Healthc Res J. 2021
  • Cognitive effects of aerobic exercise in Alzheimer's disease: a pilot randomized controlled trial. 
    Journal of Alzheimer's Disease. 2021
  • Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I. 
    Frontiers in Molecular Neuroscience. 2021
  • Longitudinal change in quality of life in neurological disorders measures over 3 years in patients with early Parkinson's disease. 
    Movement Disorders. 2021
  • Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer's mice. 
    Pharmaceuticals (Basel, Switzerland). 2021
  • Nasal oxytocin for the treatment of psychiatric disorders and pain: achieving meaningful brain concentrations. 
    Translational psychiatry. 2021
  • Neuropsychological test performances and depression in early-stage de novo Parkinson's disease. 
    Archives of Clinical Neuropsychology. 2021
  • A successful quality improvement project for detection and management of acute stroke in hospitalized patients. 
    Journal of Neuroscience Nursing. 2020
  • Antifibrotic effects of amyloid-beta and Its loss in cirrhotic liver. 
    Cells. 2020
  • Cell motility and migration as determinants of stem cell efficacy. 
    EBioMedicine. 2020
  • Double-blind placebo-controlled pilot investigation of the safety of a single dose of rapid-acting intranasal insulin in Down syndrome. 
    Drugs in R&D. 2020
  • Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. 
    Genetics in Medicine. 2020
  • Intranasal deferoxamine can improve memory in healthy C57 mice, suggesting a partially non-disease-specific pathway of functional neurologic improvement. 
    Brain and behavior. 2020
  • Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's Disease. 
    Neuroscience Letters. 2020
  • Intranasal delivery of thyroid hormones in MCT8 deficiency. 
    PloS One. 2020
  • Quality improvement in Parkinson's disease: a successful program to enhance timely administration of Levodopa in the hospital. 
    Journal of Parkinson's Disease. 2020
  • Recommendations for the organization of multidisciplinary clinical care teams in Parkinson's disease. 
    Journal of Parkinson's Disease. 2020
  • Tract-specific analysis improves sensitivity of spinal cord diffusion MRI to cross-sectional and longitudinal changes in amyotrophic lateral sclerosis. 
    Communications biology. 2020
  • Transforming dementia care through pragmatic clinical trials embedded in learning healthcare systems. 
    Journal of the American Geriatrics Society. 2020
  • Adherence to pharmacotherapy in patients with Parkinson's disease taking three and more daily doses of medication. 
    Frontiers in Neurology. 2019
  • Assessment of the performance of a modified motor scale as applied to juvenile onset Huntington's disease
    2019
  • End-of-life measures in Huntington disease: HDQLIFE meaning and purpose, concern with death and dying, and end of life planning. 
    Journal of Neurology. 2019
  • Feasibility trial of a 10-week adaptive yoga intervention developed for chronic pain patients. 
    Pain Management Nursing. 2019
  • From A to D: a unique case report of recovery after longitudinal myelitis related to lupus. 
    American Journal of Physical Medicine and Rehabilitation. 2019
  • Intranasal coadministration of a diazepam prodrug with a converting enzyme results in rapid absorption of diazepam in rats. 
    Journal of Pharmacology and Experimental Therapeutics. 2019
  • Intranasal losartan decreases perivascular beta amyloid, inflammation, and the decline of neurogenesis in hypertensive rats. 
    Neurotherapeutics. 2019
  • Neurochemical correlates of functional decline in amyotrophic lateral sclerosis. 
    Journal of Neurology, Neurosurgery and Psychiatry. 2019
  • Quantifying intranasally administered deferoxamine in rat brain tissue with mass spectrometry. 
    ACS Chemical Neuroscience. 2019
  • Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. 
    Neurology. 2019
  • Solitary bone plasmacytoma compression injury disguised as back pain: a case report
    2019
  • Unique case report of a meningeal sarcoma arising during ongoing treatment for progressing intraparenchymal glioma
    2019
  • Use and perceived effectiveness of complementary therapies in Parkinson's disease. 
    Parkinsonism & Related Disorders. 2019
  • A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. 
    Journal of Neurology. 2018
  • Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. 
    Journal of Neurology. 2018
  • Executive function: responses to aerobic exercise in Alzheimer's disease. 
    Geriatric Nursing (New York, N.Y.). 2018
  • Frontotemporal lobe degeneration as origin of scans without evidence of dopaminergic deficit. 
    Frontiers in Neurology. 2018
  • Neuropsychological test performance in Parkinsonism without dopaminergic deficiency on [123I]-FP-CIT SPECT imaging. 
    Journal of the International Neuropsychological Society. 2018
  • Pharmacokinetics in rat of P8, a peptide drug candidate for the treatment of Alzheimer's disease: stability and delivery to the brain. 
    Journal of Alzheimer's disease reports. 2018
  • Pooled analyses of phase III studies of ADS-5102 (Amantadine) extended-release capsules for dyskinesia in Parkinson's disease
    2018
  • Rates of abnormally low TOPF word reading scores in individuals failing versus passing performance validity testing. 
    Assessment. 2018
  • Rescue therapies for seizure emergencies: new modes of administration. 
    Epilepsia. 2018
  • Screening positive for cognitive impairment: impact on healthcare utilization and provider action in primary and specialty care practices. 
    Journal of General Internal Medicine. 2018
  • Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease. 
    Movement Disorders. 2018
  • What predicts falls in Parkinson disease? Observations from the Parkinson's Foundation registry. 
    Neurology. Clinical practice. 2018
  • A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. 
    Neurology. 2017
  • A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington's disease. 
    Neurodegenerative Disease Management. 2017
  • Diagnostic accuracy and confidence in the clinical detection of cognitive impairment in early-stage Parkinson disease. 
    Journal of Geriatric Psychiatry and Neurology. 2017
  • Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. 
    Journal of the Neurological Sciences. 2017
  • Genetics of Huntington disease. 
    Handbook of Clinical Neurology. 2017
  • Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis Type I. 
    Human Gene Therapy. 2017
  • Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease. 
    Journal of the Neurological Sciences. 2017
  • Intranasal delivery of a novel amnion cell secretome prevents neuronal damage and preserves function in a mouse multiple sclerosis model. 
    Scientific Reports. 2017
  • Intranasal insulin treatment of an experimental model of moderate traumatic brain injury. 
    Journal of Cerebral Blood Flow and Metabolism. 2017
  • NMDA receptor antibody encephalitis presenting with enhancing lesion and seizures. 
    Neurology. Clinical practice. 2017
  • National randomized controlled trial of virtual house calls for Parkinson disease. 
    Neurology. 2017
  • Oxytocin enhances observational fear in mice. 
    Nature communications. 2017
  • Reliability and validity of the HD-PRO-TriadTM, a health-related quality of life measure designed to assess the symptom triad of Huntington's disease
    2017
  • Research priorities to advance the health and health care of older adults with multiple chronic conditions. 
    Journal of the American Geriatrics Society. 2017
  • Clinical-genetic associations in the Prospective Huntington at Risk Observational Study (PHAROS): implications for clinical trials. 
    JAMA neurology. 2016
  • Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. 
    Parkinsonism & Related Disorders. 2016
  • Food consumption and activity levels increase in rats following intranasal Hypocretin-1. 
    Neuroscience Letters. 2016
  • HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). 
    Quality of Life Research. 2016
  • HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, speech difficulties, and swallowing difficulties. 
    Quality of Life Research. 2016
  • Health care delivery practices in Huntington's disease specialty clinics: an international survey
    2016
  • Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning. 
    Neurotoxicology. 2016
  • Intranasal drug delivery bypasses the blood–brain barrier
    2016
  • MECR mutations cause childhood-onset dystonia and optic atrophy, a mitochondrial fatty acid synthesis disorder. 
    American Journal of Human Genetics. 2016
  • National randomized controlled trial of virtual house calls for people with Parkinson's disease: Interest and barriers. 
    Telemedicine Journal and e-Health. 2016
  • New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). 
    Quality of Life Research. 2016
  • Oxytocin receptor: expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. 
    Cephalalgia. 2016
  • Routine cognitive screening in a neurology practice: effect on physician behavior. 
    Neurology. Clinical practice. 2016
  • Susac syndrome with prominent dermatological findings and a prompt response to intravenous immunoglobulin, steroids, and rituximab: a case report
    2016
  • The impact of oculomotor functioning on neuropsychological performance in Huntington disease. 
    Journal of Clinical and Experimental Neuropsychology. 2016
  • Can biomarkers differentiate pain and no pain subgroups of nonverbal children with cerebral palsy? A preliminary investigation based on noninvasive saliva sampling. 
    Pain Medicine. 2015
  • Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. 
    JAMA. 2015
  • Huntington disease
    2015
  • Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. 
    Neuroscience Letters. 2015
  • Intranasal delivery of therapeutic neural stem cells to target intracerebral glioma
    2015
  • Managing residents with Parkinson's disease in long-term care
    2015
  • Metabolic disorders with clinical and radiologic features of sporadic Creutzfeldt-Jakob disease. 
    Neurology. Clinical practice. 2015
  • Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. 
    Journal of Neurology. 2015
  • Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson's disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer's and other CNS disorders
    2015
  • Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. 
    Lancet Neurology. 2015
  • Sex differences in clinical features of early, treated Parkinson's disease. 
    PloS One. 2015
  • The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. 
    Movement Disorders. 2015
  • Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. 
    Journal of Parkinson's Disease. 2015
  • . 2008;157:908-25]. 
    Neuroscience. 2014
  • . 2012 Jan 11;8:3]. 
    Molecular Pain. 2014
  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein e4 carriers with mild-moderate Alzheimer's disease
    2014
  • Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD Study. 
    Frontiers in Aging Neuroscience. 2014
  • Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease. 
    Journal of the American Medical Directors Association. 2014
  • Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. 
    JAMA neurology. 2014
  • Experience, knowledge, and opinions about childhood genetic testing in Batten disease. 
    Molecular Genetics and Metabolism. 2014
  • Eye-specific gene expression following embryonic ethanol exposure in zebrafish: roles for heat shock factor 1. 
    Reproductive Toxicology. 2014
  • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. 
    JAMA neurology. 2014
  • Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer's and Parkinson's disease. 
    Cell Transplantation. 2014
  • Intranasal delivery, a quick and effective way to deliver therapeutics to the brain. 
    AAPS (American Association of Pharmaceutical Scientists) Newsmagazine. 2014
  • Intranasal insulin: a potential therapeutic for post-traumatic stress disorder and Alzheimer's. 
    Minn Physician. 2014
  • Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinsons disease. 
    Brain Research. 2014
  • Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 
    JAMA neurology. 2014
  • Mobility, mood and site of care impact health related quality of life in Parkinson's disease. 
    Parkinsonism & Related Disorders. 2014
  • Post-traumatic stress disorder: new approach may help prevent, as well as treat, this devastating disorder
    2014
  • Treatment of myoclonus-dystonia syndrome with tetrabenazine. 
    Parkinsonism & Related Disorders. 2014
  • Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. 
    Neurogenetics. 2013
  • Falls in Parkinson disease: analysis of a large cross-sectional cohort. 
    Journal of Parkinson's Disease. 2013
  • Intranasal administration of CNS therapeutics to awake mice. 
    Journal of visualized experiments. 2013
  • Managing juvenile Huntington's disease. 
    Neurodegenerative Disease Management. 2013
  • Mindfulness-based stress reduction for family caregivers: a randomized controlled trial. 
    The Gerontologist. 2013
  • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. 
    Neurology. 2012
  • Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. 
    Neurology. 2012
  • Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. 
    American Journal of Human Genetics. 2012
  • Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states: . 
    Molecular Pain. 2012
  • Detection of postoperative sleep-disordered breathing using a portable monitoring device. 
    Sleep & breathing = Schlaf & Atmung. 2012
  • Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. 
    Experimental Brain Research. 2012
  • Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. 
    Drug delivery and translational research. 2012
  • Intranasal delivery of growth differentiation factor 5 to the central nervous system. 
    Drug delivery. 2012
  • Intranasal delivery of insulin via the olfactory nerve pathway. 
    Journal of Pharmacy and Pharmacology. 2012
  • Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. 
    Neuroscience Letters. 2012
  • Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. 
    Molecular Genetics and Metabolism. 2012
  • Population stratification may bias analysis of PGC-1alpha as a modifier of age at Huntington disease motor onset. 
    Human Genetics. 2012
  • Special delivery: intranasal treatments bypass blood-brain barrier to treat Alzheimer's and other brain disorders. 
    Minn Physician. 2012
  • Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats. 
    Neurobiology of Disease. 2012
  • TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. 
    Biochemical and Biophysical Research Communications. 2012
  • The functional neuroanatomy of decision-making. 
    Journal of Neuropsychiatry and Clinical Neurosciences. 2012
  • Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. 
    Neurology. 2011
  • Ethanol-induced microphthalmia is not mediated by changes in retinoic acid or sonic hedgehog signaling during retinal neurogenesis. 
    Alcoholism, Clinical and Experimental Research. 2011
  • Genetic testing in clinical practice. 
    Continuum (Minneapolis, Minn.). 2011
  • Impulsive behavior and associated clinical variables in Parkinson's disease. 
    Psychosomatics. 2011
  • Intranasal delivery of CNS therapeutics. 
    AAPS (American Association of Pharmaceutical Scientists) Newsmagazine. 2011
  • Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. 
    Journal of Neuroscience. 2011
  • Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice. 
    Journal of Molecular Neuroscience. 2011
  • Motor end plate innervation loss in diabetes and the role of insulin. 
    Journal of Neuropathology and Experimental Neurology. 2011
  • Neuropsychological profile of parkin mutation carriers with and without Parkinson disease: the CORE-PD Study. 
    Journal of the International Neuropsychological Society. 2011
  • Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. 
    Neurology. 2011
  • Recruiting and retaining family caregivers to a randomized controlled trial on mindfulness-based stress reduction. 
    Contemporary Clinical Trials. 2011
  • Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. 
    Consultant Pharmacist. 2011
  • Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. 
    Brain. 2011
  • Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. 
    Rejuvenation research. 2011
  • Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. 
    Molecular Pain. 2010
  • Challenges assessing clinical endpoints in early Huntington disease. 
    Movement Disorders. 2010
  • Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB). 
    Alzheimer Disease and Associated Disorders. 2010
  • Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. 
    Archives of Neurology. 2010
  • Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. 
    Journal of Drug Targeting. 2010
  • Intranasal delivery of stem cells and genetically engineered cells to the brain. 
    Drug Deliv Technol. 2010
  • Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. 
    Archives of Neurology. 2010
  • Production and fate of the sea lamprey migratory pheromone. 
    Fish Physiology and Biochemistry. 2010
  • Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. 
    Rejuvenation research. 2010
  • Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. 
    Journal of Clinical and Experimental Neuropsychology. 2010
  • Sexual and relationship satisfaction among persons with young-onset Parkinson's disease. 
    Journal of Sexual Medicine. 2010
  • Striatal and white matter predictors of estimated diagnosis for Huntington disease. 
    Brain Research Bulletin. 2010
  • Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. 
    Molecular Pharmaceutics. 2010
  • Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. 
    Archives of Neurology. 2009
  • Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer's disease. 
    Archives of Biochemistry and Biophysics. 2009
  • Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. 
    Journal of Pharmacology and Experimental Therapeutics. 2009
  • Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. 
    Journal of Pharmaceutical Sciences. 2009
  • Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. 
    Journal of Pharmacology and Experimental Therapeutics. 2009
  • Prominent phenotypic variability associated with mutations in Progranulin. 
    Neurobiology of Aging. 2009
  • A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. 
    Parkinsonism & Related Disorders. 2008
  • Delivery of interferon-beta to the monkey nervous system following intranasal administration. 
    Neuroscience. 2008
  • Elements of attention in HIV-infected adults: evaluation of an existing model. 
    Journal of Clinical and Experimental Neuropsychology. 2008
  • Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. 
    Neurology. 2008
  • Intranasal administration delivers peptoids to the rat central nervous system. 
    Neuroscience Letters. 2008
  • Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. 
    BMC Neuroscience. 2008
  • Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. 
    Journal of Alzheimer's Disease. 2008
  • Neurocognition in individuals co-infected with HIV and hepatitis C. 
    Journal of Addictive Diseases. 2008
  • New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. 
    Neuro-Oncology. 2008
  • Replication of association between ELAVL4 and Parkinson disease: the GenePD study. 
    Human Genetics. 2008
  • The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. 
    BMC Medicine. 2008
  • Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. 
    Brain. 2007
  • Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. 
    Movement Disorders. 2007
  • Verbal episodic memory declines prior to diagnosis in Huntington's disease. 
    Neuropsychologia. 2007
  • A new locus for dominant hereditary spastic paraplegia maps to chromosome 2p12. 
    Neurogenetics. 2006
  • Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. 
    BMC Medical Genetics. 2006
  • Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. 
    American Journal of Human Genetics. 2006
  • Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes. 
    Movement Disorders. 2005
  • Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid. 
    Journal of Molecular Neuroscience. 2005
  • Antigliadin antibodies in Huntington's disease. 
    Neurology. 2004
  • Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. 
    Clinical Neuropharmacology. 2004
  • Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. 
    Neurogenetics. 2004
  • Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. 
    Journal of Neuroimmunology. 2004
  • The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. 
    Journal of Stroke and Cerebrovascular Diseases. 2004
  • A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. 
    American Journal of Human Genetics. 2003
  • Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. 
    Archives of Neurology. 2003
  • Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. 
    Neurology. 2003
  • Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. 
    Human Molecular Genetics. 2003
  • Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. 
    American Journal of Medical Genetics. Part A. 2003
  • Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. 
    American Journal of Human Genetics. 2003
  • Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. 
    Annals of Neurology. 2003
  • Predictors of nursing home placement in Huntington disease. 
    Neurology. 2003
  • Seeking clarity through the genetic lens: a work in progress. 
    Annals of Neurology. 2003
  • Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. 
    Brain Research. 2002
  • Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. 
    Neuroscience Letters. 2001
  • Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study. 
    Acta Neuropathologica. 2000
  • Pure hippocampal sclerosis: a rare cause of dementia mimicking Alzheimer's disease. 
    Neurology. 2000
  • Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. 
    Brain Research. 1996
  • Quantitative analysis of the olfactory pathway for drug delivery to the brain. 
    Brain Research. 1995
  • Clinical characteristics of chronic Creutzfeldt-Jakob disease. 
    Journal of Geriatric Psychiatry and Neurology. 1994
  • Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. 
    Molecular and Chemical Neuropathology. 1994
  • Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. 
    Brain Research. 1994
  • Seizures in Alzheimer's disease: clinicopathologic study. 
    Journal of Geriatric Psychiatry and Neurology. 1994
  • Serum cytokine levels in patients with Alzheimer's disease. 
    Clinical and Diagnostic Laboratory Immunology. 1994
  • Transforming growth factor beta in Alzheimer's disease. 
    Clinical and Diagnostic Laboratory Immunology. 1994
  • Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms. 
    Journal of Neuroimmunology. 1994
  • Pick's disease versus Alzheimer's disease: a comparison of clinical characteristics. 
    Neurology. 1993
  • Silica-ELISA method improves detection and quantitation of minor glycolipid components in lipid mixtures and of other antigens. 
    Journal of Immunological Methods. 1993
  • A clinicopathological study of CT scans in Alzheimer's disease. 
    Journal of the American Geriatrics Society. 1992
  • Altered aspartate in Alzheimer neurofibrillary tangles. 
    Neurochemical Research. 1992
  • Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. 
    Alzheimer Disease and Associated Disorders. 1992
  • Deletion in the prion protein gene in a demented patient. 
    Human Molecular Genetics. 1992
  • Multiple sclerosis dementia. 
    Neurology. 1992
  • Racemized D-aspartate in Alzheimer neurofibrillary tangles. 
    Brain Research Bulletin. 1992
  • Risk factors in Alzheimer's disease: a clinicopathologic study. 
    Neurology. 1992
  • Neuropathologically confirmed Alzheimer's disease: clinical diagnoses in 394 cases. 
    Journal of Geriatric Psychiatry and Neurology. 1991
  • Seasonal distribution of births in Alzheimer's disease. 
    International Psychogeriatrics. 1991
  • Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. 
    Neurology. 1990
  • GM-1 treatment of Alzheimer's disease. A pilot study of safety and efficacy. 
    Archives of Neurology. 1990
  • Immunogold labeling of Alzheimer paired helical filaments with ganglioside MAB A2B5. 
    Alzheimer Disease and Associated Disorders. 1990
  • D-aspartate in human brain. 
    Journal of Neurochemistry. 1987
  • Ganglioside monoclonal antibody (A2B5) labels Alzheimer's neurofibrillary tangles. 
    Neurology. 1987
  • Glial fibrillary acidic protein and Alzheimer's disease. 
    Neurochemical Research. 1985
  • Human brain tubulin purification: decrease in soluble tubulin with age. 
    Neurochemical Research. 1985
  • A comparison of peripheral and central human muscarinic cholinergic receptor affinities for psychotropic drugs. 
    Biological Psychiatry. 1982
  • Postmortem stability of dopamine-sensitive adenylate cyclase, guanylate cyclase, ATPase, and GTPase in rat striatum. 
    Journal of Neurochemistry. 1981
  • Stimulation of guanylate cyclase by EDTA and other chelating agents. 
    Biochimica et Biophysica Acta. 1981
  • Effect of dopamine on activation of rat striatal adenylate cyclase by free Mg2+ and guanyl nucleotides. 
    Journal of Neurochemistry. 1980
    • Editorial Article
  • Recommendations for virtual administration of the PSP Rating Scale [editorial]. 
    Movement Disorders.  37. 2022
  • Intronic pentanucleotide expansion in the replication factor 1 gene (RFC1) is a major cause of adult-onset ataxia [editorial]. 
    Neurology. Genetics.  6. 2020
  • Attention training improves attention and gait in Parkinson disease: a pilot study [editorial]. 
    Parkinsonism & Related Disorders.  60. 2019
  • Defining pediatric Huntington disease: time to abandon the term Juvenile Huntington Disease [editorial]?. 
    Movement Disorders.  34. 2019
  • Parkinson's disease physiotherapy: specialisation adds value [editorial]. 
    Lancet Neurology.  17. 2018
  • The AGING Initiative experience: a call for sustained support for team science networks [editorial]. 
    Health research policy and systems.  16. 2018
  • Challenges of multidisciplinary care in Parkinson's disease [editorial]. 
    Lancet Neurology.  12. 2013
  • Family history in juvenile Huntington disease: do the signs point to "yes" or "very doubtful" [editorial]?. 
    Neurology.  80. 2013
  • Insulin to treat Alzheimer's disease: just follow your nose [editorial]?. 
    Expert Review of Clinical Pharmacology.  5. 2012
  • Posterior cortical atrophy: neuropathological correlations [editorial]. 
    Archives of Neurology.  53. 1996
  • The clinical correlates of high-titer IgG anti-GM1 antibodies [editorial]. 
    Annals of Neurology.  36. 1994
  • The tears of the physician [editorial]. 
    JAMA.  263. 1990
  • Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer's brain [editorial]. 
    Lancet (London, England).  1. 1985
    • Chapter
  • Comportment: structure and function. 
    Neurology and Neuropsychiatry. 2013
    • Conference Paper
  • Intranasal delivery bypasses the blood-brain barrier to deliver and target insulin and other therapeutics to the central nervous system [invited speaker]
    2013
  • Intranasal delivery bypasses the blood-brain barrier to deliver and target stem cells and other therapeutics to the central nervous system [invited speaker]
    2013
  • Intranasal delivery bypasses the blood-brain barrier to deliver and target therapeutics to the central nervous system [invited speaker]
    2013
  • Intranasal delivery bypasses the blood-brain barrier to deliver and target therapeutics to the central nervous system [invited speaker]
    2013
  • Intranasal delivery bypasses the blood-brain barrier to deliver and target therapeutics to the central nervous system [invited speaker]
    2013
  • Changes in physical activity and nutrition in a behavioral intervention pilot study: Passport to Brain Wellness
    2010
    • Conference Poster
  • Outcomes of an embedded resource and education program for patients and families with memory loss [poster]
    2017
  • Performance on cognitive screening is associated with increased retrospective healthcare utilization [poster]
    2015
  • Pharmacokinetics of a diazepam prodrug/enzyme combination following nasal administration in rats for treatment of seizure emergencies [poster]
    2015
  • Routine cognitive screening in a neurology practice: impact on physician behavior [poster]
    2015
  • The Minnesota Memory Project: baseline data from a longitudinal observational study of aging [poster]
    2015
  • Failure on cognitive screening predicts increased healthcare utilization [poster]
    2014
  • Routine cognitive screening in a general neurology clinic: impact on physician behavior [poster]
    2014
  • Detection of deferoxamine using liquid chromatography/mass spectrometry with electrospray ionization [poster]
    2013
  • Evidence-based provider tools for efficient identification and management of cognitive impairment [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Intranasally administered deferoxamine induces neuroprotection in a 6-OHDA model of Parkinson's disease [poster]
    2013
  • Lavender essential oil improved sleep in residents of a memory care assisted living facility [poster]
    2013
  • The effect of intranasal rapid acting insulin on ApoE4 carriers with mild-moderate Alzheimer's disease [poster]
    2013
  • Feasibility of the mini-cog as a standardized cognitive screen in HealthPartners patients aged 70 and older [poster]
    2012
  • Intranasal deferoxamine treatment in a rat model of Parkinsons disease: preliminary results [poster]
    2012
  • Pedicle screw fixation in cervical trauma [poster]
    2012
  • Specific types of memory complaints may provide an early warning sign of cognitive impairment in community dwelling older adults [poster]
    2012
  • The 6th Vital Sign Project: does cognitive screening in the elderly population improve clinical care [poster]?
    2012
  • Tractography of the human cervical spine nerve roots [poster]
    2012
  • Nasal delivery of lidocaine decreases carrageenan-induced orofacial pain [poster]
    2011
  • Changes in cognitive function and plasma biomarkers in a pilot trial of a multi-domain intervention to prevent cognitive decline [poster]
    2010
  • Clinical features of autopsy confirmed cases of early and late onset Alzheimer's disease [poster]
    2010
  • Intranasal deferoxamine improves memory and decreases GSK3B activity in C57 mice [poster]
    2010
  • Intranasal lidocaine blocks orofacial pain with few behavioral side effects [poster]
    2010
  • MBSR (mindfulness-based stress reduction) for caregivers of people with dementia: the Balance Study [poster]
    2010
  • The Minnesota Memory Project [poster]
    2010
    • Review
  • Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design [review]. 
    Alzheimer's & dementia. 2023
  • Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions [review]. 
    Parkinsonism & Related Disorders. 2023
  • The burden of dementia spectrum disorders and associated comorbid and demographic features [review]. 
    Clinics in Geriatric Medicine. 2023
  • Brain glucose hypometabolism and iron accumulation in different brain regions in Alzheimer's and Parkinson's diseases [review]. 
    Pharmaceuticals (Basel, Switzerland). 2022
  • Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations [review]. 
    Translational neurodegeneration. 2022
  • Mechanisms of intranasal deferoxamine in neurodegenerative and neurovascular disease [review]. 
    Pharmaceuticals (Basel, Switzerland). 2021
  • The global pandemic has permanently changed the state of practice for pre-DBS neuropsychological evaluations [review]. 
    Parkinsonism & Related Disorders. 2021
  • Integrated care in Parkinson's disease: a systematic review and meta-analysis [meta-analysis, review, systematic review]. 
    Movement Disorders. 2020
  • Intranasal insulin: a treatment strategy for addiction [review]. 
    Neurotherapeutics. 2020
  • Does cognitive training prevent cognitive decline: a systematic review [systematic review]. 
    Annals of Internal Medicine. 2018
  • Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review [systematic review]. 
    Annals of Internal Medicine. 2018
  • Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review [systematic review]. 
    Annals of Internal Medicine. 2018
  • Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review [systematic review]. 
    Annals of Internal Medicine. 2018
  • Genetic counseling and testing for Huntington's disease: a historical review [review]. 
    American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics. 2017
  • Interventions to prevent age-related cognitive decline, mild cognitive impairment, and clinical Alzheimer's-type dementia [review]
    2017
  • Oxytocin and migraine headache [review]. 
    Headache. 2017
  • Disability rating scales in Parkinson's disease: Critique and recommendations [review]. 
    Movement Disorders. 2016
  • Creutzfeldt-Jakob Disease in the hospital setting: a case report and review [review]. 
    Minnesota Medicine. 2013
  • Incomplete nonsense-mediated decay facilitates detection of a multi-exonic deletion mutation in SGCE [review]. 
    Clinical Genetics. 2013
  • Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence [review]
    2013
  • Intranasal insulin to treat and protect against posttraumatic stress disorder [review]. 
    Journal of Nervous and Mental Disease. 2013
  • Intranasal treatment of central nervous system dysfunction in humans [review]. 
    Pharmaceutical Research. 2013
  • Brain insulin signaling and Alzheimer's disease: current evidence and future directions [review]. 
    Molecular Neurobiology. 2012
  • Intranasal treatment of neurodegenerative diseases and stroke [review]. 
    Frontiers in bioscience (Scholar edition). 2012
  • Therapy in Huntington's disease: where are we [review]?. 
    Current Neurology and Neuroscience Reports. 2012
  • Intranasal insulin as a therapeutic option in the treatment of cognitive impairments [review]. 
    Experimental Gerontology. 2011
  • The evaluation of rapidly progressive dementia [review]. 
    The neurologist. 2011
  • Intranasal delivery to the central nervous system: mechanisms and experimental considerations [review]. 
    Journal of Pharmaceutical Sciences. 2010
  • Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease [review]. 
    BMC Neuroscience. 2008
  • Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS [review]. 
    Journal of Neuroimmune Pharmacology. 2007
    • Abstract
  • A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson's disease treated with Levodopa-Carbidopa Intestinal Gel and deep brain stimulation [abstract]. 
    Journal of the Neurological Sciences. 2021
  • IMPACT Learning Health Network: transforming care through embedded pragmatic clinical trials in health care settings that serve people with dementia [abstract]. 
    Journal of patient-centered research and reviews. 2021
  • The NIA IMPACT Collaboratory: transforming dementia care rhrough embedded pragmatic clinical trials [abstract]
    2020
  • Implementation of a mindfulness based dementia-care program within a healthcare system [abstract]. 
    Innovation in aging. 2019
  • Chord Study: the power of music through participation in the giving voice chorus [abstract]. 
    Alzheimer's & dementia. 2018
  • Correlation between evaluation and documentation of neurologic deficit by EMS and ED of patients with acute ischemic stroke [abstract]. 
    Neurology. 2018
  • Analysis of run sheets of EMS serving a metropolitan comprehensive stroke center [abstract]. 
    Neurology. 2017
  • Clinical characteristics and healthcare utilization of Hmong patients presenting with stroke [abstract]. 
    Neurology. 2017
  • Clinical characteristics of Hmong patients presenting with acute ischemic stroke [abstract]. 
    Stroke. 2017
  • Cognitive screening results from the Medicare annual wellness visit in a primary care practice [abstract]. 
    Alzheimer's & dementia. 2017
  • Mindfulness for early Alzheimer's Disease: a pilot study [abstract]. 
    Alzheimer's & dementia. 2017
  • The Twin Cities ALS Research Consortium: a model for regional collaboration in advancing research for people living with ALS [abstract]
    2017
  • Minnesota memory project: use of the Alberta Smell Test in a longitudinal aging cohort [abstract]. 
    Alzheimer's & dementia. 2016
  • Outcomes from routine cognitive screening in a health care system [abstract]. 
    Alzheimer's & dementia. 2016
  • Outcomes of a dementia resource and education program imbedded in a health care system [abstract]. 
    Alzheimer's & dementia. 2016
  • Delivery of therapeutics via the intranasal route for the treatment of neurodegenerative diseases [abstract]. 
    Neurotherapeutics. 2015
  • Changes in physical activity and nutrition in a behavioral intervention pilot study - passport to brain wellness [abstract]. 
    Clinical Medicine & Research. 2010
    • Audio Document
  • Belonging, burnout and the importance of well-being [podcast]
    2023
  • Changes that improve care and experience [podcast]
    2023
  • City of Saint Paul's diversity and equity efforts [podcast]
    2023
  • George Floyd global memorial art exhibit [podcast]
    2023
  • The practice of self-care and finding community [podcast]
    2023
  • The realities of responding to microaggressions [podcast]
    2023
  • Connecting with communities [podcast]
    2022
  • Equity and education in the community [podcast]
    2022
  • Equity in the medical workplace [podcast]
    2022
  • Giving back through mentorship [podcast]
    2022
  • Microaggressions: upstander vs. bystander [podcast]
    2022
  • Off the charts: examining the health equity emergency [podcast]
    2022
  • Pathways to racial equity outdoors [podcast]
    2022
  • Penumbra Center for racial healing
    2022
  • Study aims to show impact of ‘Ecosystem’ of support for people with dementia and their caregivers [interview]. 
    MinnPost. 2022
    • Audio-Visual Document
  • The waiting room (on Alzheimer's disease). Broadcast on FM107 Radio.
    2016
    • Book
  • Caregiver guide for mid to late stage Huntington's disease: for long-term care facilities and in-home care agencies
    2015
    • Patent
  • Methods for protecting and treating traumatic brain injury and concussion with intranasal insulin
    2021
  • Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
    2021
  • Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
    2021
  • Methods for treating patients with impaired awareness of hypoglycemia
    2021
  • Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
    2017
  • Device and method for delivering therapeutic substances to the maxillary sinus of a patient
    2014
  • Lipid growth factor formulations
    2014
  • Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage
    2014
  • Method of treating Parkinson's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
    2014
  • Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
    2014
    • Quick Info